^
Association details:
| Biomarker: | EGFR mutation + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
23 High Tumour Pd-L1 Predicts Early Resistance to First Generation EGFR TKIs in EGFR-Mutant Lung Cancer
Published date:
08/06/2020
Excerpt:
Patients with Stage IIIB/IV lung adenocarcinoma harboring a sensitizing EGFR mutation and treated with first‐line, first or second‐generation TKI...69% received erlotinib...Compared to patients with PD‐L1 low/negative tumours those with high PD‐L1 (n = 9; 13%) had significantly shorter PFS...OS (10.8 vs 25.8 months, HR 0.22 95% CI 0.09‐0.58, P = .001).
DOI:
https://doi.org/10.1111/ajco.13417
